The FDA has granted approval for two gene therapies to treat sickle cell disease. One of them is the first to utilize the CRISPR editing tool.
On Friday, regulators gave their approval for two gene therapies that aim to cure sickle cell disease, a painful and hereditary blood disorder prevalent among Black individuals in the U.S. The FDA announced that individuals 12 years and older with severe forms of the illness can receive one-time treatments. One treatment, produced by Vertex Pharmaceuticals
READ MORE